Loading
FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.
Plays an essential role for cellular polarisation, directed cell migration and modulating cell-cell contact.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming CDK4/6 Inhibition. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.99, genetic association 0.18, somatic mutation 0.98, animal model 0.44). IntOGen calls it a driver in 45 cohorts (15 activating, 30 loss-of-function), covering Acute Myeloid Leukaemia, Angiosarcoma, Anal Squamous Cell Carcinoma, Basal Cell Carcinoma, Burkitt Lymphoma, Bladder/Urinary Tract and others.
In plain words · FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.
FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.
Plays an essential role for cellular polarisation, directed cell migration and modulating cell-cell contact. Location: Cell membrane; Nucleus (UniProt).
No product in this corpus aims at FAT1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA FAT1: RNA tissue enhanced (choroid plexus 82 nTPM); high antibody staining in 6 normal tissues; highest cancer staining glioma (6 of 12 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Head and neck squamous cell carcinoma, Lung cancer (all types), Bladder & urothelial cancer, Breast cancer (all types), Oesophageal cancer, Cervical cancer, Nasopharyngeal carcinoma and more); Open Targets associates it with 3 specific cancer types at or above 0.5 (head and neck squamous cell carcinoma, squamous cell lung carcinoma, cervical squamous cell carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q14517; CIViC gene FAT1; IntOGen FAT1; Human Protein Atlas FAT1 tissue; Open Targets ENSG00000083857 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Dunne et al, Genomics, 1995, "Molecular cloning and tissue expression of FAT, the human homologue of the Drosophila fat gene that is located on chromosome 4q34-q35 and encodes a putative adhesion molecule". Source.
Sources: HGNC HGNC:3595 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14517 (protein name, function text, keywords and locations (REST API)); CIViC gene FAT1 (1 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer (GraphQL API, CC0)); Open Targets ENSG00000083857 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.53, colorectal cancer 0.59, oesophageal cancer 0.59, urinary bladder cancer 0.60, cervical cancer 0.53, melanoma 0.62 (GraphQL API, CC0)); IntOGen FAT1 (driver in 45 cohorts (Act 15, LoF 30); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Plays an essential role for cellular polarisation, directed cell migration and modulating cell-cell contact. Location: Cell membrane; Nucleus (UniProt). Locus 4q35.2 (HGNC).
RNA: tissue enhanced (choroid plexus 82 nTPM), detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Caudate, Colon, Esophagus, Nasopharynx, Pancreas.
Medium only: cervical cancer, head and neck cancer, melanoma, pancreatic cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FAT1" OR ABSTRACT:"FAT1" OR TITLE:"FAT atypical cadherin 1" OR ABSTRACT:"FAT atypical cadherin 1" OR TITLE:"Protocadherin Fat 1" OR ABSTRACT:"Protocadherin Fat 1" OR TITLE:"CDHF7" OR ABSTRACT:"CDHF7" OR TITLE:"CDHR8" OR ABSTRACT:"CDHR8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAT1, not a curated reading list.
Shares Nasopharyngeal carcinoma, Cervical cancer, Bladder & urothelial cancer, CIViC.
Shares Nasopharyngeal carcinoma, Oesophageal cancer, Cervical cancer, IntOGen.
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, IntOGen, Head and neck squamous cell carcinoma.
Shares Nasopharyngeal carcinoma, Cervical cancer, CIViC, IntOGen.
Shares Nasopharyngeal carcinoma, Oesophageal cancer, CIViC, IntOGen.
Shares Nasopharyngeal carcinoma, IntOGen, Head and neck squamous cell carcinoma, Breast cancer (all types).
Shares Nasopharyngeal carcinoma, IntOGen, Breast cancer (all types), Open Targets Platform.
Shares Nasopharyngeal carcinoma, IntOGen, Open Targets Platform.